The validity and responsiveness of the EQ-5D measure of health-related quality of life in an adolescent population with persistent major depression

J Ment Health. 2013 Apr;22(2):101-10. doi: 10.3109/09638237.2013.779366.

Abstract

Background: Despite a preference for economic evaluations to measure outcomes in terms of quality-adjusted life years, generic measures of outcome are rarely used in mental health research involving young people.

Aims: To explore the validity and responsiveness of the EQ-5D measure of health-related quality of life in adolescents with major depression.

Method: Data came from a clinical trial involving adolescents with persistent major depression (n = 199). Construct validity was tested using socio-demographic constructs and baseline clinical outcome scores. To assess convergent validity, correlation between EQ-5D and clinical outcome scores was tested. To assess responsiveness, the mean change in EQ-5D scores of participants categorised as improved versus not improved on clinical outcome measures was tested.

Results: Significant differences in mean EQ-5D score were found for co-morbidity and three of four severity measures but not gender, age, treatment history or suicide attempts. Mean EQ-5D scores were significantly correlated with all clinical outcome measures, although relationships were moderate or weak. A change in mean EQ-5D score was significantly related to clinical assessments of improvement on all outcome measures.

Conclusions: Results provide initial evidence to support the relevance of the EQ-5D in adolescents with major depression, but this evidence is weak. Replication studies are needed to assess the generalisability of these findings.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Child
  • Cognitive Behavioral Therapy / methods
  • Depressive Disorder, Major / diagnosis*
  • Depressive Disorder, Major / psychology*
  • Depressive Disorder, Major / therapy
  • Female
  • Follow-Up Studies
  • Health Status*
  • Humans
  • Male
  • Outcome Assessment, Health Care
  • Psychometrics
  • Quality of Life / psychology*
  • Quality-Adjusted Life Years
  • Reproducibility of Results
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Severity of Illness Index
  • Surveys and Questionnaires
  • United Kingdom

Substances

  • Antidepressive Agents, Second-Generation
  • Serotonin Uptake Inhibitors